Abbott Leverages Nostalgia to Boost Colon Cancer Screening Awareness
Event summary
- Abbott launches 'The (Second) Talk' campaign featuring John Stamos and Jodie Sweetin to promote colon cancer screening.
- Cologuard test, a noninvasive screening option, has been used over 23 million times since 2014.
- Colorectal cancer is the second-leading cause of cancer-related deaths in the U.S.
- Cologuard Plus test detects 95% of colon cancers and many precancers in clinical studies.
The big picture
Abbott's campaign targets the rising incidence of colorectal cancer in younger adults, leveraging celebrity endorsements to overcome screening reluctance. The strategy aligns with broader industry trends toward noninvasive, at-home diagnostic solutions. With over 23 million Cologuard tests used since 2014, Abbott is positioning itself as a leader in preventive healthcare diagnostics.
What we're watching
- Campaign Effectiveness
- Whether Abbott's nostalgic marketing approach will drive significant increases in screening rates among the target demographic.
- Market Penetration
- The pace at which Cologuard and Cologuard Plus tests will gain market share against traditional colonoscopy screening methods.
- Regulatory Compliance
- How evolving guidelines from the American Cancer Society and U.S. Preventive Services Task Force will impact Abbott's screening products.
Related topics